Mass Spectrometry Analysis Of Young And Aged Mice And Human Alzheimer’S Disease With Lewy Body Pathology Using On-Slide Tissue Digestion
Diagnosing brain disorders like Alzheimer’s and Lewy body disease often happens too late, after significant damage has already occurred. A major challenge is that aging, the biggest risk factor, causes subtle changes in the brain that can predispose it to these conditions. To better understand these early changes, scientists have developed an innovative technique that allows for a very detailed look at the brain’s molecular makeup from even tiny tissue samples. This new approach uses a sophisticated analytical tool called mass spectrometry, which can identify and measure thousands of different molecules. They optimized a method called “on-slide tissue digestion,” where brain tissue is prepared directly on a microscope slide, making it possible to analyze the complete set of proteins (the “proteome”) and sugar molecules (the “glycome”) in specific brain regions. Using this advanced method, researchers first examined the brains of aged mice. They found increases in proteins important for brain cell communication, suggesting that aging leads to a remodeling of these connections, known as synapses. They also observed subtle changes in certain complex sugar molecules called chondroitin sulfates. When they applied this technique to human brain samples from individuals with Alzheimer’s and Lewy body disease, particularly when both conditions were present, they discovered significant reductions in specific chondroitin sulfate levels. They also noted differences in proteins that make up the “extracellular matrix” – the scaffolding that supports brain cells – as well as other sugar-modified proteins (a process called “glycosylation”) and mitochondrial proteins, which are crucial for cell energy. These findings are important because they reveal specific molecular alterations that occur with aging and in neurodegenerative diseases. This new platform provides a powerful tool for identifying early indicators, or “biomarkers,” that could eventually lead to earlier diagnosis and the development of new treatments for these devastating conditions.
Source: link to paper